EX-10.1



 Exhibit 10.1 

Execution Version 

SECURITIES PURCHASE AGREEMENT 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 18, 2016 by and among Spring Bank
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). 

RECITALS 
 A. The Company
and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and Exchange
Commission (the “SEC”) under the Securities Act of 1933, as amended; and 
 B. The Investors wish to purchase from the Company, and
the Company wishes to sell and issue to the Investors, upon the terms and subject to the conditions stated in this Agreement, (i) shares (the “Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common
Stock”) and (ii) warrants in the form attached hereto as Exhibit B to purchase Common Stock (each, a “Common Warrant” and collectively, the “Common Warrants”). 

C. Contemporaneously with the sale of the Shares and Common Warrants, the parties hereto will execute and deliver a Registration Rights
Agreement, in the form attached hereto as Exhibit C (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain registration rights in respect of the Shares and the Common
Warrant Shares (as defined below) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, and applicable state securities laws. 

In consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows: 
 1. Definitions. For the purposes of this Agreement, the following
terms shall have the meanings set forth below: 
 “Affiliate” means, with respect to any Person, any other Person which
directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common Control with, such Person. 

“Business Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general
transaction of business. 
 “Closing” has the meaning set forth in Section 3.1. 

“Closing Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if
the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market as reported by Bloomberg Financial L.P. (based on a
Trading Day from 9:30 a.m. Eastern Time to 4:02 p.m. Eastern Time); (b) the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board or (c) if the Common Stock is not then listed or
quoted on the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by the Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the Common Stock so reported; or (d) in all other cases, the fair market value of a share of Common Stock as determined by a good faith determination of the Company’s Board of Directors 







 “Closing Date” has the meaning set forth in Section 3.1. 

“Closing Securities” means the Shares and the Common Warrants. 

“Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 

“Common Warrants” has the meaning set forth in the recitals to this Agreement. 

“Common Warrant Shares” means the shares of Common Stock issuable upon exercise of the Common Warrants. 

“Company Intellectual Property” has the meaning set forth in Section 4.14. 

“Company’s Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933
Act) of the Company. 
 “Control” (including the terms “controlling”, “controlled by” or “under
common control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Disclosure Schedules” has the meaning set forth in Section 4. 

“Environmental Laws” has the meaning set forth in Section 4.15. 

“FDA” has the meaning set forth in Section 4.30. 

“GAAP” has the meaning set forth in Section 4.17. 

“IPO Registration Statement” means the Company’s registration statement (File No. 333-208875), including a
prospectus, as amended at the time it became effective on May 5, 2016, including the information deemed pursuant to Rule 430A, 430B or 430C under the 1933 Act to be part of such registration statement at the time of its effectiveness. 

“Losses” has the meaning set forth in Section 8.2. 

“Material Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations,
financial condition or business of the Company and its subsidiary taken as a whole, (ii) the legality or enforceability of any of the Transaction Documents or (iii) the ability of the Company to perform its obligations under the
Transaction Documents. 

  
 2 








 “Material Contract” means any contract, instrument or other agreement to which
the Company is a party or by which it is bound that has been filed or was required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K. 

“Nasdaq” means The Nasdaq Capital Market. 

“Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint
stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

“Placement Agent” means William Blair & Company, L.L.C. 

“Press Release” has the meaning set forth in Section 9.7. 

“Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall be The Nasdaq Capital Market. 
 “Registration Rights
Agreement” has the meaning set forth in the recitals to this Agreement. 
 “Required Investors” has the meaning
set forth in the Registration Rights Agreement. 
 “SEC Filings” has the meaning set forth in Section 4. 

“Securities” means the Shares, the Common Warrants and the Common Warrant Shares. 

“Shares” has the meaning set forth in the recitals to this Agreement. 

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be
deemed to include the location and/or reservation of borrowable shares of Common Stock). 
 “Subscription Amount” means, as
to an Investor, the aggregate amount to be paid for the Closing Securities purchased hereunder as specified opposite such Investor’s name on Exhibit A attached hereto, under the column entitled “Aggregate Purchase Price of Closing
Securities,” in U.S. Dollars and in immediately available funds. 
 “Subsidiary” of any Person means another Person,
an amount of the voting securities, other voting ownership or voting partnership interests of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such voting interests, 50% or more
of the equity interests of which) is owned directly or indirectly by such first Person. 

  
 3 








 “Trading Day” means (i) a day on which the Common Stock is listed or quoted and
traded on its Principal Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded in the over-the-counter
market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets” by Pink Sheets LLC
(or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business
Day. 
 “Trading Market” means whichever of the New York Stock Exchange, the NYSE Amex Equities (formerly the American
Stock Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 

“Transfer Agent” has the meaning set forth in Section 7.4(a). 

“Transaction Documents” means this Agreement, the Common Warrants and the Registration Rights Agreement. 

“1933 Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated
thereunder. 
 “1934 Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules
and regulations promulgated thereunder. 
 2. Purchase and Sale of the Shares and Common Warrants. On the Closing Date, upon the terms
and subject to the conditions set forth herein, the Company will issue and sell, and the Investors will purchase, severally and not jointly, for a price per Share and associated Common Warrant of $9.12 (i) the number of Shares set forth opposite the
name of such Investor under the heading “Number of Shares to be Purchased” on Exhibit A attached hereto and (ii) a Common Warrant to purchase one share of Common Stock for every one Share purchased at Closing. The Common
Warrants shall have an exercise price equal to $10.79 per Common Warrant Share (subject to adjustment as provided therein).
 3.
Closing. 
 3.1. Upon the satisfaction of the conditions set forth in Section 6, the completion of the purchase and sale of the
Closing Securities (the “Closing”) shall occur remotely via exchange of documents and signatures at a time (the “Closing Date”) to be agreed to by the Company and the Investors but in no event later than the third
Business Day after the date hereof, and of which the Investors will be notified in advance by the Placement Agent.
 3.2. On the Closing
Date, each Investor shall deliver or cause to be delivered to the Company the Subscription Amount via wire transfer of immediately available funds pursuant to the wire instructions delivered to such Investor by the Company on or prior to the Closing
Date. 
 3.3. At or before the Closing, the Company shall deliver or cause to be delivered to each Investor the following: 

(a) a number of Shares, registered in the name of the Investor, equal to the number of Shares set forth opposite the name of such Investor
under the heading “Number of Shares to be Purchased” on Exhibit A attached hereto; and 

  
 4 








 (b) a Common Warrant, registered in the name of such Investor, to purchase up to the number of
Common Warrant Shares set forth opposite the name of such Investor under the heading “Number of Common Warrant Shares Underlying Common Warrant Purchased” on Exhibit A attached hereto. 

4. Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors that, except as set
forth in the schedules delivered herewith (collectively, the “Disclosure Schedules”) or as otherwise described in the Company’s filings pursuant to the 1934 Act (collectively, the “SEC Filings”), which qualify
these representations and warranties in their entirety: 
 4.1. Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own or lease its
properties. The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing
necessary unless the failure to so qualify has not had and would not reasonably be expected to have a Material Adverse Effect. The Company’s subsidiary is duly organized, validly existing and in good standing under the laws of its
jurisdiction of its incorporation and has all requisite power and authority to carry on its business as now conducted and to own or lease its properties. The Company’s subsidiary is duly qualified to do business as a foreign corporation
and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and would not reasonably be expected
to have a Material Adverse Effect. 
 4.2. Authorization. The Company has the requisite corporate power and authority and has
taken all requisite corporate action necessary for, and no further action on the part of the Company, its officers, directors and stockholders is necessary for, (i) the authorization, execution and delivery of the Transaction Documents,
(ii) the authorization of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Closing Securities. The Transaction Documents
constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general
applicability, relating to or affecting creditors’ rights generally and to general equitable principles. 
 4.3.
Capitalization. The Company is authorized under its Certificate of Incorporation to issue 200,000,000 shares of Common Stock. The Company’s disclosure of its issued and outstanding capital stock in its most recent SEC Filing
containing such disclosure was accurate in all material respects as of the date indicated in such SEC Filing. All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued and are
fully paid and nonassessable; none of such shares were issued in violation of any pre-emptive rights; and such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights of third
parties. No Person is entitled to pre-emptive or similar statutory or contractual rights with respect to the issuance by the Company of any securities of the Company. There are no outstanding warrants, options, convertible securities or
other rights, agreements or arrangements of any character under which the Company is or may be obligated to issue any equity securities of any kind and except as contemplated by this Agreement. Except for the Registration Rights Agreement,
there are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by
them. Except as provided in the Registration Rights Agreement, no Person has the right to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection with the registration of
securities of the Company for its own account or for the account of any other Person. 
 The issuance and sale of the Closing Securities
hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any
outstanding security. 

  
 5 








 The Company does not have outstanding stockholder purchase rights or “poison pill” or
any similar arrangement in effect giving any Person the right to purchase any equity interest in the Company upon the occurrence of certain events. 

4.4. Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement,
will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed
by applicable securities laws. The Common Warrants have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued. The Common Warrant Shares have been duly and validly authorized and
reserved for issuance and, upon exercise of the Common Warrants in accordance with their terms, including the payment of any exercise price therefor, will be validly issued, fully paid and nonassessable and will be free and clear of all encumbrances
and restrictions (other than those created by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws.

4.5. Consents. The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale
of the Closing Securities require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings
pursuant to applicable state and federal securities laws and the rules and regulations of Nasdaq which the Company undertakes to file within the applicable time periods and other than the registration statement required to be filed by the
Registration Rights Agreement. Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof, the Company has taken all action necessary to exempt (i) the issuance and sale of the Closing
Securities and (ii) the other transactions contemplated by the Transaction Documents from the provisions of any stockholder rights plan or other “poison pill” arrangement, any anti-takeover, business combination or control share law
or statute binding on the Company or to which the Company or any of its assets and properties is subject that is or could reasonably be expected to become applicable to the Investors as a result of the transactions contemplated hereby, including
without limitation, the issuance of the Closing Securities and the ownership, disposition or voting of the Shares or the Common Warrant Shares by the Investors or the exercise of any right granted to the Investors pursuant to this Agreement or the
other Transaction Documents. 
 4.6. Use of Proceeds. The net proceeds of the sale of the Closing Securities hereunder shall be
used by the Company for working capital and general corporate purposes.
 4.7. No Material Adverse Change. Since December 31,
2015, except as identified and described in the SEC Filings, there has not been: 
 (i) any change in the assets, liabilities, financial
condition or operating results of the Company from that reflected in the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, except for changes in the ordinary course of business which
have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 
 (ii) any
declaration or payment by the Company of any dividend, or any authorization or payment by the Company of any distribution, on any of the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company;

 (iii) any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company; 

  
 6 








 (iv) any waiver, not in the ordinary course of business, by the Company of a material right or
of a material debt owed to it; 
 (v) any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the
Company, except in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results or business of the Company (as such business is presently conducted); 

(vi) any change or amendment to the Company’s Certificate of Incorporation or By-laws, or material change to any material contract or
arrangement by which the Company or is bound or to which any of its assets or properties is subject; 
 (vii) any material labor
difficulties or, to the Company’s Knowledge, labor union organizing activities with respect to employees of the Company; 
 (viii) any
material transaction entered into by the Company other than in the ordinary course of business; 
 (ix) the loss of the services of any key
employee, or material change in the composition or duties of the senior management of the Company; 
 (x) the loss or, to the Company’s
Knowledge, threatened loss of any customer which has had or would reasonably be expected to have a Material Adverse Effect; or 
 (xi) any
other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect. 
 4.8. SEC
Filings. 
 (a) The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
under the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material). At the time of filing thereof, the
SEC Filings complied as to form in all material respects with the requirements of the 1934 Act. 
 4.9. No Conflict, Breach, Violation or
Default. The execution, delivery and performance of the Transaction Documents by the Company and the issuance and sale of the Closing Securities in accordance with the provisions thereof will not, except for such violations, conflicts or
defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (i) conflict with or result in a breach or violation of (a) any of the terms and provisions of, or constitute a default
under, the Company’s Certificate of Incorporation or the Company’s By-laws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through the Electronic Data Gathering, Analysis,
and Retrieval system (the “EDGAR system”)), or (b) assuming the accuracy of the representations and warranties in Section 5, any applicable statute, rule, regulation or order of any governmental agency or body or any court,
domestic or foreign, having jurisdiction over the Company or its subsidiary, or any of their assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company or its subsidiary or give to others any rights of termination, amendment, acceleration or cancellation (with or without
notice, lapse of time or both) of, any Material Contract. This Section does not relate to matters with respect to tax status, which are the subject of Section 4.10, employee relations and labor matters, which are the subject of
Section 4.13, and environmental laws, which are the subject of Section 4.15. 

  
 7 








 4.10. Tax Matters. The Company and its subsidiary have timely prepared and filed all
tax returns required to have been filed by them with all appropriate governmental agencies and timely paid all taxes shown thereon or otherwise owed by them. The charges, accruals and reserves on the books of the Company in respect of taxes for
all fiscal periods are adequate in all material respects, and there are no material unpaid assessments against the Company nor, to the Company’s Knowledge, any basis for the assessment of any additional taxes, penalties or interest for any
fiscal period or audits by any federal, state or local taxing authority except for any assessment which is not material to the Company. All taxes and other assessments and levies that the Company is required to withhold or to collect for
payment have been duly withheld and collected and paid to the proper governmental entity or third party when due. There are no tax liens or claims pending or, to the Company’s Knowledge, threatened against the Company or any of its assets
or property. There are no outstanding tax sharing agreements or other such arrangements between the Company and any other corporation or entity. 

4.11. Title to Properties. The Company and its subsidiary have good and marketable title to all real properties and all other
properties and assets owned by them, in each case free from liens, encumbrances and defects, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and the Company and its subsidiary
hold any leased real or personal property under valid and enforceable leases with no exceptions, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

4.12. Certificates, Authorities and Permits. The Company and its subsidiary possess adequate certificates, authorities or permits
issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by them, except where failure to so possess would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse
Effect. The Company and its subsidiary have not received any written notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that would reasonably be expected to have a Material Adverse Effect,
individually or in the aggregate, on the Company. 
 4.13. Labor Matters. 

(a) Neither the Company nor its subsidiary is party to or bound by any collective bargaining agreements or other agreements with labor
organizations. To the Company’s knowledge, Company and its subsidiary have not violated in any material respect any laws, regulations, orders or contract terms, affecting the collective bargaining rights of employees, labor organizations
or any laws, regulations or orders affecting employment discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours. 

(b) No material labor dispute with the employees of the Company or its subsidiary, or with the employees of any principal supplier,
manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.
 4.14.
Intellectual Property. Except as expressly contemplated by the SEC Filings, the Company and its subsidiary own, possess, license or have other rights to use, the patents and patent applications, copyrights, trademarks, service marks,
trade names, service names and trade secrets described in the SEC Filings as necessary or material for use in connection with their business and which the failure to so have would have or reasonably be expected to result in a Material Adverse Effect
(collectively, the “Company Intellectual Property”). There is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by any Person that the Company’s business or the business of its
subsidiary as now conducted infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of another. To the Company’s Knowledge, there is no existing infringement by another Person of any of
the Intellectual Property Rights that would have or would reasonably be expected to have a Material Adverse Effect. The Company and its subsidiary have taken reasonable security measures to protect the secrecy, confidentiality and value of all of
their Intellectual Property Rights, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

  
 8 








 4.15. Environmental Matters. Neither the Company nor its subsidiary is in violation
of any statute, rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the
environment or human exposure to hazardous or toxic substances (collectively, “Environmental Laws”), has released any hazardous substances regulated by Environmental Law on to any real property that it owns or operates, has received any
written notice or claim it is liable for any off-site disposal or contamination pursuant to any Environmental Laws, which violation, release, notice, claim, or liability would reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect,; and to the Company’s Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim. 

4.16. Legal Proceedings. There are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to
which the Company or its subsidiary is or may reasonably be expected to become a party or to which any property of the Company or its subsidiary is or may reasonably be expected to become the subject that, individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect. 
 4.17. Financial Statements. The financial statements included in
each SEC Filing comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and
present fairly, in all material respects, the financial position of the Company as of the dates shown and its results of operations and cash flows for the periods shown, subject in the case of unaudited financial statements to normal, immaterial
year-end audit adjustments, and such financial statements have been prepared in conformity with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”) (except as may be
disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and, in the case of quarterly financial statements, as permitted by Form 10-Q under the 1934
Act). Except as set forth in the financial statements of the Company included in the SEC Filings filed prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course
of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. 

4.18. Insurance Coverage. The Company and its subsidiary maintain in full force and effect insurance coverage that is customary for
comparably situated companies for the business being conducted and properties owned or leased by the Company and its subsidiary, and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims and risks
against which it is customary for comparably situated companies to insure. 
 4.19. Compliance with Nasdaq Continued Listing
Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of
the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq. 

4.20. Brokers and Finders. Other than the Placement Agent, no Person will have, as a result of the transactions contemplated by the
Transaction Documents, any valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company.
No Investor shall have any obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 4.20 that may be due in connection with the
transactions contemplated by this Agreement or the Transaction Documents. 

  
 9 








 4.21. No Directed Selling Efforts or General Solicitation. Neither the Company nor
any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of the Closing Securities. 

4.22. No Integrated Offering. Neither the Company nor its subsidiary nor any Person acting on their behalf has, directly or
indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(2) for the exemption from registration for
the transactions contemplated hereby or would require registration of the Closing Securities under the 1933 Act. 
 4.23. Private
Placement. Assuming the accuracy of the representations and warranties of the Investors set forth in Section 5, the offer and sale of the Closing Securities to the Investors as contemplated hereby is exempt from the registration
requirements of the 1933 Act. The issuance and sale of the Closing Securities does not contravene the rules and regulations of Nasdaq. 

4.24. Questionable Payments. Neither the Company nor its subsidiary nor, to the Company’s
Knowledge, any of their current or former directors, officers, employees, agents or other Persons acting on behalf of the Company or its subsidiary, has on behalf of the Company or its subsidiary in connection with its business: (a) used any
corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payments to any governmental officials or employees from corporate funds;
(c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets which is in violation of law; (d) made any false or fictitious entries on the books and records of the Company; or (e) made any unlawful
bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any nature. 
 4.25. Transactions with
Affiliates. None of the executive officers or directors of the Company or its subsidiary and, to the Company’s Knowledge, none of the employees of the Company or its subsidiary is presently a party to any transaction with the Company
(other than as holders of stock options and/or warrants, and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is
an officer, director, trustee or partner. 
 4.26. Internal Controls. The Company has established and maintains disclosure
controls and procedures (as defined in Rules 13a-15 and 15d-15 under the 1934 Act), which are designed to ensure that material information relating to the Company, including its subsidiary, is made known to the Company’s principal executive
officer and its principal financial officer by others within those entities. Since the end of the Company’s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Company’s internal
control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal
control over financial reporting. The Company is not aware of any change in its internal controls over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial reporting. 
 4.27. Disclosures. Neither the Company nor any Person
acting on its behalf has provided the Investors or their agents or counsel with any information that constitutes or would reasonably be expected to constitute material, non-public information which according to applicable law, rule or regulation was
required to have been disclosed publicly by the Company or its subsidiary, but which has not been so disclosed, other than with respect to the transactions contemplated hereby and except as will be disclosed in the 8-K Filing (as defined
below). The SEC Filings and the slide presentation presented to the Investors by the Company in connection with the offer and sale of the Closing Securities, when considered together, do not contain any untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading. The Company understands and confirms that the Investors will rely on the
foregoing representations in effecting transactions in securities of the Company.

  
 10 








 4.28. Required Filings. Except for the transactions contemplated by this Agreement,
including the acquisition of the Closing Securities contemplated hereby, no event or circumstance has occurred or information exists with respect to the Company or its business, properties, operations or financial condition, which, under applicable
law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the SEC Filings are being incorporated by reference into an effective
registration statement filed by the Company under the 1933 Act).
 4.29. Investment Company. The Company is not required to be
registered as, and is not an Affiliate of, and immediately following the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 

4.30. Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials conducted by or, to the
Company’s Knowledge, on behalf of the Company that are described in the SEC Filings were and, if still pending, are being, conducted in all material respects in accordance with the protocols submitted to the U.S. Food and Drug Administration
(the “FDA”) or any foreign governmental body exercising comparable authority, procedures and controls pursuant to, where applicable, accepted professional and scientific standards, and all applicable laws and regulations; the descriptions
of the studies, tests and preclinical and clinical trials conducted by or, to the Company’s Knowledge, on behalf of the Company, and the results thereof, contained in the SEC Filings are accurate and complete in all material respects; the
Company is not aware of any other studies, tests or preclinical and clinical trials, the results of which call into question the results described in the SEC Filings; and the Company has not received any notices or correspondence from the FDA, any
foreign, state or local governmental body exercising comparable authority or any Institutional Review Board requiring the termination, suspension, material modification or clinical hold of any studies, tests or preclinical or clinical trials
conducted by or on behalf of the Company. 
 4.31. Manipulation of Price. The Company has not, and, to the Company’s
Knowledge, no Person acting on its behalf has taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the
Securities. 
 4.32. Anti-Bribery and Anti-Money Laundering Laws. Each of the Company, its subsidiary and any of their respective
officers, directors, supervisors, managers, agents, or employees, are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws, including but not limited to, any applicable law,
rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17,
1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope or (B) anti-money laundering laws, including but not limited to, applicable
federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code section 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and
international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United
States representative to the group or organization continues to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder. 

5. Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly, represents and
warrants to the Company that: 
 5.1. Organization and Existence. Such Investor is a validly existing corporation, limited
partnership or limited liability company and has all requisite corporate, partnership or limited liability company power and authority to enter into and consummate the transactions contemplated by the Transaction Documents and to carry out its
obligations hereunder and thereunder, and to invest in the Securities pursuant to this Agreement. 

  
 11 








 5.2. Authorization. The execution, delivery and performance by such Investor of the
Transaction Documents to which such Investor is a party have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in
accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally. 

5.3. Purchase Entirely for Own Account. The Securities to be received by such Investor hereunder will be acquired for such
Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and such Investor has no present intention of selling, granting any participation in, or
otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state
securities laws. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period of time. Such Investor is not a broker-dealer registered with the SEC under the
1934 Act or an entity engaged in a business that would require it to be so registered. 
 5.4. Investment Experience. Such
Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the
investment contemplated hereby. 
 5.5. Disclosure of Information. Such Investor has had an opportunity to receive, review and
understand all information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities, and has conducted and
completed its own independent due diligence. Such Investor acknowledges that copies of the SEC Filings are available on the EDGAR system. Based on the information such Investor has deemed appropriate, and without reliance upon any
Placement Agent, it has independently made its own analysis and decision to enter into the Transaction Documents. Such Investor is relying exclusively on its own sources of information, investment analysis and due diligence (including
professional advice it deems appropriate) with respect to the execution, delivery and performance of the Transaction Documents, the Securities and the business, condition (financial and otherwise), management, operations, properties and prospects of
the Company, including but not limited to all business, legal, regulatory, accounting, credit and tax matters. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect
such Investor’s right to rely on the Company’s representations and warranties contained in this Agreement. 
 5.6. Restricted
Securities. Such Investor understands that the Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a
public offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances. 

5.7. Legends. It is understood that, except as provided below, certificates evidencing the Securities may bear the following or any
similar legend: 
 (a) “The securities represented hereby have not been registered with the Securities and Exchange Commission or the
securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not be transferred unless (i) such securities have been registered for sale pursuant to the
Securities Act of 1933, as amended, (ii) such securities may be sold pursuant to Rule 144, or (iii) the Company has received an opinion of counsel reasonably satisfactory to it that such transfer may lawfully be made without
registration under the Securities Act of 1933, as amended.” 

  
 12 








 (b) If required by the authorities of any state in connection with the issuance of sale of the
Securities, the legend required by such state authority. 
 5.8. Accredited Investor. Such Investor is (a) an “accredited
investor” within the meaning of Rule 501 under the 1933 Act and has executed and delivered to the Company a questionnaire in substantially the form attached hereto as Exhibit D (the “Investor Questionnaire”), which such
Investor represents and warrants is true, correct and complete. Such investor is (b) a sophisticated institutional investor with sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks and
merits of its purchase of the Securities. Such Investor has determined based on its own independent review and such professional advice as it deems appropriate that its purchase of the Securities and participation in the transactions
contemplated by the Transaction Documents (i) are fully consistent with its financial needs, objectives and condition, (ii) comply and are fully consistent with all investment policies, guidelines and other restrictions applicable to such Investor,
(iii) have been duly authorized and approved by all necessary action, (iv) do not and will not violate or constitute a default under such Investor’s charter, by-laws or other constituent document or under any law, rule, regulation, agreement or
other obligation by which such Investor is bound and (v) are a fit, proper and suitable investment for such Investor, notwithstanding the substantial risks inherent in investing in or holding the Securities.

5.9. Placement Agent. Such Investor hereby acknowledges and agrees that (a) the Placement Agent is acting solely as placement agent
in connection with the execution, delivery and performance of the Transaction Documents and is not acting as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary for such Investor, the Company or any other
person or entity in connection with the execution, delivery and performance of the Transaction Documents, (b) the Placement Agent has not made and will not make any representation or warranty, whether express or implied, of any kind or character and
has not provided any advice or recommendation in connection with the execution, delivery and performance of the Transaction Documents, (c) the Placement Agent will not have any responsibility with respect to (i) any representations, warranties or
agreements made by any person or entity under or in connection with the execution, delivery and performance of the Transaction Documents, or the execution, legality, validity or enforceability (with respect to any person) thereof, or (ii) the
business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company, and (d) the Placement Agent will not have any liability or obligation (including without limitation, for or with respect to
any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such Investor, the Company or any other person or entity), whether in contract, tort or otherwise, to such Investor, or
to any person claiming through it, in respect of the execution, delivery and performance of the Transaction Documents. 
 5.10. No General
Solicitation. Such Investor did not learn of the investment in the Securities as a result of any general solicitation or general advertising. 

5.11. Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any
valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor. 

5.12 Short Sales and Confidentiality Prior to the Date Hereof. Other than consummating the transactions contemplated hereunder, such
Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period
commencing as of the time that such Investor was first contacted by the Company, the Placement Agent or any other Person regarding the transactions contemplated hereby and ending immediately prior to the date hereof. Notwithstanding the
foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor’s assets and the portfolio 

  
 13 








 
managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor’s assets, the representation set forth above shall only
apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement, such Investor has
maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall
constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. 

5.13 No Government Recommendation or Approval. Such Investor understands that no United States federal or state agency, or similar
agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of the Securities. 

5.14 No Intent to Effect a Change of Control. Such Investor has no present intent to effect a “change of control” of the
Company as such term is understood under the rules promulgated pursuant to Section 13(d) of the 1934 Act. 
 5.15 No Rule 506
Disqualifying Activities. Such Investor has not taken any of the actions set forth in, and is not subject to, the disqualification provisions of Rule 506(d)(1) of the 1933 Act. 

5.16 Residency. Such Investor is a resident of the jurisdiction specified below its address on the Schedule of Investors. 

6. Conditions to Closing. 

6.1. Conditions to the Investors’ Obligations. The obligation of each Investor to purchase Closing Securities at the Closing
is subject to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to itself only): 

(a) The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all material respects as of
the date hereof and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such
earlier date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date. 

(b) The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for consummation of the
purchase and sale of the Closing Securities and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect. 

(c) The Company shall have executed and delivered the Registration Rights Agreement. 

(d) The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares and the Common
Warrant Shares. 

  
 14 








 (e) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice
or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the
consummation of the transactions contemplated hereby or in the other Transaction Documents. 
 (f) The Company shall have delivered a
Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), (d), (e) and
(i) of this Section 6.1. 
 (g) The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary,
dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Closing Securities,
certifying the current versions of the Certificate of Incorporation and By-laws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company. 

(h) The Investors shall have received an opinion from Wilmer Cutler Pickering Hale and Dorr LLP, the Company’s counsel, dated as of the
Closing Date, in form and substance reasonably acceptable to the Placement Agent and addressing such legal matters as the Investors may reasonably request. 

(i) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect
to public trading in the Common Stock. 
 6.2. Conditions to Obligations of the Company. The Company’s obligation to sell
and issue Closing Securities at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: 

(a) The representations and warranties made by the Investors in Section 5 hereof shall be true and correct in all material respects as of
the date hereof, and shall be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and as of said date. The Investors shall have performed in all material respects all
obligations and covenants herein required to be performed by them on or prior to the Closing Date. 
 (b) The Investors shall have executed
and delivered the Registration Rights Agreement and each Investor Questionnaire. 
 (c) Any Investor purchasing Closing Securities at the
Closing shall have paid in full its Subscription Amount to the Company. 
 6.3. Termination of Obligations to Effect Closing; Effects.

 (a) The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as
follows: 

  
 15 








 (i) Upon the mutual written consent of the Company and Investors that agreed to purchase a
majority of the Closing Securities to be issued and sold pursuant to this Agreement; 
 (ii) By the Company if any of the conditions set
forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been waived by the Company;
 (iii) By an Investor
(with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived by the Investor; or 

(iv) By either the Company or any Investor (with respect to itself only) if the Closing has not occurred on or prior to November 30, 2016;

 provided, however, that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect the Closing shall not then
be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its
obligation to effect the Closing. 
 (b) In the event of termination by the Company or any Investor of its obligations to effect the Closing
pursuant to this Section 6.3, written notice thereof shall be given to the other Investors by the Company and the other Investors shall have the right to terminate their obligations to effect the Closing upon written notice to the Company and
the other Investors. Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right
of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. 

7. Covenants and Agreements of the Company. 

7.1. No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would
conflict or interfere in any material respect with the Company’s obligations to the Investors under the Transaction Documents. 
 7.2.
Nasdaq Listing. The Company will use commercially reasonable efforts to continue the listing and trading of its Common Stock on Nasdaq and, in accordance, therewith, will use commercially reasonable efforts to comply in all respects with
the Company’s reporting, filing and other obligations under the bylaws or rules of such market or exchange, as applicable. 
 7.3.
Termination of Covenants. The provisions of Sections 7.1 and 7.2 shall terminate and be of no further force and effect on the date on which the Company’s obligations under the Registration Rights Agreement to register or
maintain the effectiveness of any registration covering the Registrable Securities (as such term is defined in the Registration Rights Agreement) shall terminate. 

7.4. Removal of Legends.

(a) In connection with any sale, assignment, transfer or other disposition of the Shares by an Investor pursuant to Rule 144 or pursuant
to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor, the Company shall cause the transfer agent
for the Common Stock (the “Transfer Agent”) to remove any 

  
 16 








 
restrictive legends related to the book entry account holding such Shares and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive legends, provided
that the Company has received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection therewith.

(b) Subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation reasonably
acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares (i) have been sold or transferred pursuant to an effective registration statement, (ii) have been sold pursuant to
Rule 144, or (iii) are eligible for resale under Rule 144(b)(1) or any successor provision (such earliest date, the “Effective Date”), the Company shall (A) deliver to the Transfer Agent irrevocable instructions that the
Transfer Agent shall make a new, unlegended entry for such book entry Shares, and (B) cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected
under the 1933 Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement. The Company agrees that following the Effective Date or at such time as such legend is no longer required
under this Section 7.4, it will, within three Trading Days of the delivery by an Investor to the Company or the Transfer Agent of a certificate representing shares issued with a restrictive legend and receipt from the Investor by the Company and the
Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith (the “Share Delivery Date”) deliver or cause to be delivered to such Investor a
certificate representing such Shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this
Section 7.4.Shares subject to legend removal hereunder may be transmitted by the Transfer Agent to the Investor by crediting the account of the Investor’s prime broker with the DTC System as directed by such Investor. The Company shall be
responsible for the fees of its Transfer Agent and all DTC fees associated with such issuance. If the Company fails to effect delivery of any such Shares on or before the applicable Share Delivery Date and if after such date, due to the
Company’s continuing failure to deliver such Shares, such Investor purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the holder of shares of Common Stock that such Investor
anticipated receiving from the Company without any restrictive legend (a “Buy-In”), then the Company shall, within three (3) Trading Days after such Investor’s request and in such Investor’s sole discretion, either (i) pay
cash to the Investor in an amount equal to such Investor’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company’s obligation to deliver such Shares shall
terminate, or (ii) promptly honor its obligation to deliver to such Investor such shares of Common Stock and pay cash to the Investor in an amount equal to the excess (if any) of such Investor’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased in the Buy-In over the product of (a) such number of shares of Common Stock purchased in the Buy-in, times (b) the Closing Bid Price on the Share Delivery Date. 

(c) Each Investor, severally and not jointly with the other Investors, agrees with the Company (i) that such Investor will sell any Shares
pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an 

  
 17 








 
exemption therefrom, (ii) that if Shares are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein and (iii) that if, after
the effective date of the registration statement covering the resale of the Shares, such registration statement is not then effective and the Company has provided notice to such Investor to that effect, such Investor will sell Shares only in
compliance with an exemption from the registration requirements of the 1933 Act. 
 7.5. Subsequent Equity Sales. 

(a) From the date hereof until sixty (60) days after the effective date of the registration statement covering the resale of the Shares,
without the consent of the Required Investors, the Company shall not (A) issue shares of Common Stock or Common Stock Equivalents or (B) file with the SEC a registration statement under the 1933 Act relating to any shares of Common Stock or Common
Stock Equivalents, except pursuant to the terms of agreements to which the Company is currently a party. Notwithstanding the foregoing, the provisions of this Section 7.5(a) shall not apply to (i) the issuance of the Securities
hereunder, (ii) the issuance of Common Stock or Common Stock Equivalents upon the conversion or exercise of any securities of the Company outstanding on the date hereof or outstanding pursuant to clause (iii), (iv) or (v) below, (iii) the
issuance of any Common Stock or Common Stock Equivalents pursuant to any Company stock-based compensation plans, (iv) the issuance of any Common Stock or Common Stock Equivalents in connection with a transaction with an unaffiliated third party that
includes a bona fide commercial relationship with the Company (including any joint venture, marketing or distribution arrangement, strategic alliance, collaboration agreement or corporate partnering, intellectual property license agreement or
acquisition agreement with the Company); provided, however, that the aggregate number of shares of Common Stock issued pursuant to clause (iv) during the ninety (90) day restricted period shall not exceed 10% of the total number of shares of Common
Stock issued and outstanding immediately following the Closing. 
 (b) The Company shall not, and shall use its commercially reasonable
efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated with the offer or sale
of the Securities in a manner that would require the registration under the 1933 Act of the sale of the Securities to the Investors, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any
trading market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. 

7.6. Short Sales and Confidentiality After the Date Hereof. Each Investor covenants that neither it nor any Affiliates acting on
its behalf or pursuant to any understanding with it will execute any Short Sales during the period from the date hereof until the earlier of such time as (i) the transactions contemplated by this Agreement are first publicly announced or (ii) this
Agreement is terminated in full. Each Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to
it in connection with this transaction (including the existence and terms of this transaction). Each Investor understands and acknowledges that the SEC currently takes the position that coverage of Short Sales of shares of the Common Stock
“against the box” prior to effectiveness of a resale registration statement with securities included in such registration statement would be a violation of Section 5 of the 1933 Act, as set forth in Item 239.10 of the Securities Act
Rules Compliance and Disclosure Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance. 

  
 18 








 8. Survival and Indemnification. 

8.1. Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing of
the transactions contemplated by this Agreement for the applicable statute of limitations. 
 8.2. Indemnification. The Company
agrees to indemnify and hold harmless each Investor and its Affiliates and their respective directors, officers, trustees, members, managers, employees and agents, and their respective successors and assigns, from and against any and all losses,
claims, damages, liabilities and expenses (including without limitation reasonable attorney fees and disbursements and other expenses reasonably incurred in connection with investigating, preparing or defending any action, claim or proceeding,
pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the
part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person. 

8.3. Conduct of Indemnification Proceedings. Any person entitled to indemnification hereunder shall
(i) give prompt notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the
indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the
expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or
(c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the
indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and
provided, further, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall
materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or
expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or
delayed, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim
or litigation. No indemnified party will, except with the consent of the indemnifying party, consent to entry of any judgment or enter into any settlement. 

9. Miscellaneous. 
 9.1.
Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company or each of the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate
its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Securities in a transaction complying with applicable securities laws without the prior written consent of the Company or the other Investors,
provided such assignee agrees in writing to be bound by the provisions hereof that apply to Investors. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the
parties. Without limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity
securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed
to refer to such Person and the term “Securities” shall be deemed to refer to the securities received by the Investors in connection with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

  
 19 








 9.2. Counterparts; Faxes; E-mail. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile or e-mail, which shall be deemed an original. 

9.3. Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 
 9.4. Notices. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by facsimile,
then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three
days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier. All
notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the other party: 

If to the Company: 
 Spring Bank
Pharmaceuticals, Inc. 
 113 Cedar Street 

Milford, Massachusetts 01757 

Attention: Chief Financial Officer 

Fax: (508) 381-0347 

Email: jfreve@springbankpharm.com 

With a copy to: 
 Wilmer Cutler
Pickering Hale and Dorr LLP 
 60 State Street 

Boston, Massachusetts 02109 

Attention: Stuart M. Falber 

Fax: (617) 526-5000 
 If to the
Investors: 
 to the addresses set forth on the signature pages hereto. 

9.5. Expenses. The parties hereto shall pay their own costs and expenses in connection herewith regardless of whether the
transactions contemplated hereby are consummated; it being understood that each of the Company and each Investor has relied on the advice of its own respective counsel.

9.6. Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and (a) prior to the Closing, Investors that agreed to purchase a majority of the Shares to be issued and
sold pursuant to this Agreement and (b) following the Closing, the Required Investors. Notwithstanding the foregoing, this Agreement may not be amended and the 

  
 20 








 
observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to all Investors in
the same fashion. Any amendment or waiver effected in accordance with this paragraph shall be binding upon (i) prior to Closing, each Investor and (ii) following the Closing, each holder of any Securities purchased under this Agreement at the time
outstanding, and in each case, each future holder of all such Securities and the Company. 
 9.7. Publicity. Except as set forth
below, no public release or announcement concerning the transactions contemplated hereby shall be issued by the Investors without the prior consent of the Company (which consent shall not be unreasonably withheld), except as such release or
announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Investors shall allow the Company, to the extent reasonably practicable in the circumstances, reasonable
time to comment on such release or announcement in advance of such issuance. The Company shall not include the name of any Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any SEC
Filing) without the prior written consent of such Investor. By 8:30 a.m. (New York City time) on the Business Day immediately following the date this Agreement is executed, the Company shall issue a press release disclosing all material terms
of transactions contemplated by this Agreement (the “Press Release”). No later than 5:30 p.m. (New York City time) on the first Business Day following the date this Agreement is executed, the Company will file a Current Report on Form
8-K (the “8-K Filing”) attaching the press release described in the foregoing sentence as well as copies of the Transaction Documents. In addition, the Company will make such other filings and notices in the manner and time required
by the SEC or Nasdaq. The parties acknowledge that from and after the issuance of the Press Release, no Investor shall be in possession of any material, nonpublic information received from the Company or any of its respective officers,
directors, employees or agents, with respect to the transactions contemplated hereby that is not disclosed in the Press Release. The Company shall not, and shall cause each of its officers, directors, employees and agents, not to, provide any
Investor with any such material, nonpublic information regarding the Company from and after the filing of the Press Release without the express prior written consent of such Investor. 

9.8. Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by
applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any
provision of law which renders any provision hereof prohibited or unenforceable in any respect. 
 9.9. Entire Agreement. This
Agreement, including the signature pages, Exhibits and the Disclosure Schedules, and the other Transaction Documents constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all
prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof. 

9.10. Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other
actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 

9.11. Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in
accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in
New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated
hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the
parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such
suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been 

  
 21 








 
brought in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS
BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.  
 9.12. Independent Nature of Investors’ Obligations and Rights. The
obligations of each Investor under any Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under any
Transaction Document. The decision of each Investor to purchase Closing Securities pursuant to the Transaction Documents has been made by such Investor independently of any other Investor. Nothing contained herein or in any Transaction
Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its
investment hereunder and that no Investor will be acting as agent of such Investor in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Investor shall be entitled to
independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party
in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same Transaction Documents for the purpose of closing a transaction with multiple Investors and not because it was required or
requested to do so by any Investor. 
 9.13. Limitation of Liability. Notwithstanding anything herein to the contrary, the
Company acknowledges and agrees that the liability of an Investor arising directly or indirectly under any Transaction Document of any and every nature whatsoever shall be satisfied solely out of the assets of such Investor and that no trustee,
officer, other investment vehicle or any other Affiliate of such Investor or any investor, shareholder or holder of shares of beneficial interest of such Investor shall be personally liable for any liabilities of such Investor. 

[remainder of page intentionally left blank] 

  
 22 








 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. 
  

							
	COMPANY:	 		 	SPRING BANK PHARMACEUTICALS, INC.
				
		 		 	By:	 	 /s/ Martin Driscoll

		 		 		 	Name: Martin Driscoll
		 		 		 	Title: Chief Executive Officer









							
	INVESTOR:	 		 	
		 		 	By:	 	 /s/ Ansbert Gadicke

		 		 		 	 Ansbert Gadicke
  

on behalf of
 MPM ONCOLOGY IMPACT

MANAGEMENT GP LLC
  

in its capacity as general partner of
 MPM ONCOLOGY IMPACT

MANAGEMENT LP
  

in its capacity as general partner of
 ONCOLOGY IMPACT FUND

(CAYMAN) MANAGEMENT L.P.
  

in its capacity as general partner of
 UBS ONCOLOGY IMPACT FUND
L.P.










							
	INVESTOR:	 		 	
		 		 	By:	 	Baker Bros. Advisors LP, Management Company and Investment Adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life
Sciences, L.P. and not as the general partner
				
		 		 	By:	 	 /s/ Scott L. Lessing

		 		 		 	Scott L. Lessing, President









					
	 INVESTOR:
	  	
		  	By:	  	Baker Bros. Advisors LP, Management Company and Investment Adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P. and not as the general partner
			
		  	By:	  	 /s/ Scott L. Lessing

		  		  	Scott L. Lessing, President









					
	INVESTOR: Alyeska Master Fund, LP	  	
	                      Alyeska Master Fund 2, LP	  	By:	  	 /s/ Jason Bragg

		  		  	 Name: Jason Bragg
 Title: CFO










					
	 INVESTOR: The E. Burke Ross Jr. Descendants’

GST Investment Trust 2014
	  	
		  	By:	  	 /s/ Peter Lacaillade

		  		  	 Name: Peter Lacaillade
 Title:
Trustee










					
	INVESTOR: EBR Ventures, LLC	  	
		  	By:	  	 /s/ E. Burke Ross Jr.

		  		  	 Name: E. Burke Ross Jr.
 Title: Manager, EBR
Ventures, LLC










					
	INVESTOR: CVI Investments, Inc.	  	
		  	By:	  	 /s/ Martin Kobinger

		  		  	 Name: Martin Kobinger
 Title: Investment
Manager










							
	INVESTOR: Burrage Capital Healthcare Fund I, LP	 		 		 	
		 		 	By:	 	 /s/ Chris Bardon

		 		 		 	Chris Bardon









					
	 INVESTOR:
	  	
		  	By:	  	 /s/ Kurt Eichler

		  		  	 Name: Kurt Eichler

Title: Director










							
	INVESTOR:	 	 Marilyn E. Tenzer
 Declaration of
Trust
 u/a/d 10/7/98
	  	
		 	  	By:	  	 /s/ Marilyn E. Tenzer

		 	  		  	 Name: Marilyn E. Tenzer
 Title: Trustee for the
Marilyn E. Tenzer Declaration of Trust










					
	INVESTOR: Iroquois Master Fund Ltd.	  	
		  	By:	  	 /s/ Richard Abbe

		  		  	 Name: Richard Abbe
 Title:
Director










					
	INVESTOR: Iroquois Capital Investment Group LLC	  	
		  	By:	  	 /s/ Richard Abbe

		  		  	 Name: Richard Abbe
 Title:
Director










					
	 INVESTOR: DAFNA LifeScience LP
	  	
		  	 By:
	  	 /s/ Nathan Fischel

		  		  	 Name: Nathan Fischel

Title: CEO










					
	 INVESTOR: DAFNA LifeScience Select LP
	  	
		  	 By:
	  	 /s/ Nathan Fischel

		  		  	 Name: Nathan Fischel

Title: CEO










					
	INVESTOR: Intracoastal Capital, LLC	  	
		  	By:	  	 /s/ Keith A. Goodman

		  		  	 Name: Keith A. Goodman
 Title: Authorized
Signatory










					
	INVESTOR: MLPF&S Custodian FBO	  	
	                      Anthony Argyrides IRRA	  	By:	  	 /s/ Anthony Argyrides

		  		  	 Name: Anthony Argyrides 11/16/2016

Title:










					
	 INVESTOR:
	  	
		  	 By:
	  	 /s/ Todd Brady

		  		  	 Todd Brady










					
	INVESTOR:	  	
		  	By:	  	 /s/ Nezam Afdhal

		  		  	Nezam Afdhal









					
	 INVESTOR: Parallax Biomedical Fund, LP
	  		  	
		  	 By:
	  	 /s/ Marc Pentopoulos

		  		  	Name: Marc Pentopoulos
		  		  	Title:   Managing Partner









					
	INVESTOR:	  	
		  	By:	  	 /s/ Martin Driscoll

		  		  	 Name: Martin Driscoll
 Title: CEO










					
	INVESTOR: Cynergy Healthcare Investors	  	
	                      Emerging Bridge, LLC	  	By:	  	 /s/ Patrick Adams

		  		  	 Name: Patrick Adams
 Title: Managing
Member










					
	INVESTOR:	  	
		  	By:	  	 /s/ Jonathan Freve

		  		  	 Name: Jonathan Freve
 Title: CFO










					
	INVESTOR:	  	
		  	By:	  	 /s/ David Arkowitz

		  		  	 Name: David Arkowitz
 Title: Director, Spring
Bank Pharma









 EXHIBIT A 

Schedule of Investors 
  

													
	 Investor Name and Address
	  	Number of
Shares to be
Purchased	 	  	Number of
Common Warrant
Shares
Underlying
Common Warrant
Purchased	 	  	Aggregate
Purchase Price
of Closing
Securities	 
	 UBS Oncology Impact Fund L.P.

UBS Trustees (Cayman) Ltd.,

5th Floor, Cayman Corporate Center, 27 Hospital Road

Georgetown, Grand Cayman KY1-1003
	  	 	603,070	  	  	 	603,070	  	  	$	5,499,998.40	  
	 Baker Brothers Life Sciences, L.P.

667 Madison Ave, 21st Flr

New York, NY 10065
	  	 	198,642	  	  	 	198,642	  	  	$	1,811,615.04	  
	 667, L.P.

667 Madison Ave, 21st Flr

New York, NY 10065
	  	 	20,656	  	  	 	20,656	  	  	$	188,382.72	  
	 Alyeska Master Fund, LP

77 W Wacker

Chicago, IL 60601
	  	 	116,000	  	  	 	116,000	  	  	$	1,057,920.00	  
	 Alyeska Master Fund 2, LP

77 W Wacker

Chicago, IL 60601
	  	 	84,000	  	  	 	84,000	  	  	$	766,080.00	  
	 The E. Burke Ross Jr. Descendants’

GST Investment Trust 2014

c/o SCS Financial,

One Winthrop Square, 4th Floor

Boston, MA 02110
	  	 	26,455	  	  	 	26,455	  	  	$	241,269.60	  
	 EBR Ventures, LLC

172 S. Ocean Boulevard

Palm Beach, FL 33480
	  	 	118,550	  	  	 	118,550	  	  	$	1,081,176.00	  


  
 47 









													
	 CVI Investments, Inc.

c/o Heights Capital Management

101 California Street, Suite 3250

San Francisco, CA 94111
	  	 	109,645	  	  	 	109,645	  	  	$	999,962.40	  
	 Burrage Capital Healthcare Fund I, LP

314 Commonwealth Ave.

Boston, MA 02115
	  	 	54,824	  	  	 	54,824	  	  	$	499,994.88	  
	 Kurt Eichler
	  	 	64,100	  	  	 	64,100	  	  	$	584,592.00	  
	 Marilyn E. Tenzer Declaration of Trust

u/a/d 10/7/98

111 W. Jackson Blvd., Ste. 115B

Chicago, IL 60604
	  	 	54,824	  	  	 	54,824	  	  	$	499,994.88	  
	 Iroquois Master Fund Ltd.

c/o Iroquois Capital Management, LLC

205 East 42nd Street, 20th Floor
 New York, NY 10017
	  	 	13,706	  	  	 	13,706	  	  	$	124,998.72	  
	 Iroquois Capital Investment Group LLC

c/o Iroquois Capital Management, LLC

205 East 42nd Street, 20th Floor
 New York, NY 10017
	  	 	24,671	  	  	 	24,671	  	  	$	224,999.52	  
	 DAFNA LifeScience LP

10990 Wilshire Blvd. #1400

Los Angeles, CA 90024
	  	 	16,447	  	  	 	16,447	  	  	$	149,996.64	  
	 DAFNA LifeScience Select LP

10990 Wilshire Blvd. #1400

Los Angeles, CA 90024
	  	 	10,965	  	  	 	10,965	  	  	$	100,000.80	  
	 Intracoastal Capital, LLC

245 Palm Trail

Delray Beach, FL 33483

w/ Notice to:

Intracoastal Capital LLC

2211A Lakeside Drive

Bannockburn, IL 60015
	  	 	27,410	  	  	 	27,410	  	  	$	249,979.20	  
	 MLPF&S Custodian FBO Anthony Argyrides IRRA
	  	 	21,930	  	  	 	21,930	  	  	$	200,001.60	  
	 Todd Brady
	  	 	10,964	  	  	 	10,964	  	  	$	99,991.68	  
	 Nezam Afdhal
	  	 	13,150	  	  	 	13,150	  	  	$	119,928.00	  
	 Parallax Biomedical Fund, LP

342 E. 67th St. 4B

New York, NY 10065
	  	 	12,000	  	  	 	12,000	  	  	$	109,440.00	  
	 Martin Driscoll
	  	 	21,900	  	  	 	21,900	  	  	$	199,728.00	  


  
 48 









													
	 Cynergy Healthcare Investors Emerging Bridge, LLC

6898 S. University Blvd, Suite 100

Centennial, CO 80122
	  	 	10,960	  	  	 	10,960	  	  	$	99,955.20	  
	 Jonathan Freve
	  	 	5,482	  	  	 	5,482	  	  	$	49,995.84	  
	 David Arkowitz
	  	 	4,386	  	  	 	4,386	  	  	$	40,000.32	  
	 TOTAL
	  	 	1,644,737	  	  	 	1,644,737	  	  	$	15,000,001.44	  


  
 49 








 EXHIBIT B 

Form of Common Warrant 







 EXHIBIT C 

Registration Rights Agreement 







 EXHIBIT D 

Investor Questionnaire 







 Disclosure Schedules 

None.